<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228423</url>
  </required_header>
  <id_info>
    <org_study_id>UOHI 2006-111</org_study_id>
    <nct_id>NCT00228423</nct_id>
  </id_info>
  <brief_title>Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)</brief_title>
  <acronym>CASCADE</acronym>
  <official_title>Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of clopidogrel with aspirin&#xD;
      prevents the development of blockages (atherosclerosis) in vein grafts one year after&#xD;
      coronary artery bypass surgery (CABG) compared to aspirin alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Saphenous vein graft disease remains a major limitation of coronary artery bypass graft&#xD;
      surgery (CABG). The process of saphenous vein intimal hyperplasia is mediated by platelet&#xD;
      aggregation and begins just days after surgical revascularization. Subsequently, areas of&#xD;
      intimal hyperplasia in turn develop graft atherosclerotic disease and its sequelae.&#xD;
      Clopidogrel improves outcomes in patients with atherosclerotic disease, and is effective at&#xD;
      reducing intimal hyperplasia in animal models of thrombosis. Therefore, the goal of this&#xD;
      study will be to evaluate the efficacy of clopidogrel and aspirin therapy versus aspirin&#xD;
      alone in the prevention of saphenous vein graft intimal hyperplasia following one year after&#xD;
      CABG.&#xD;
&#xD;
      Patients undergoing multi-vessel CABG and in whom at least two saphenous vein grafts will be&#xD;
      used are eligible for the study. Patients will be randomized to receive daily clopidogrel 75&#xD;
      mg or placebo, in addition to daily aspirin 162 mg, for the duration of one year starting as&#xD;
      soon as postoperative bleeding has been ruled out on the day of surgery. At the end of one&#xD;
      year, all patients will undergo coronary angiography and intravascular ultrasound assessment&#xD;
      of one saphenous vein graft as selected by randomization. The study will be powered to test&#xD;
      the hypothesis that clopidogrel and aspirin will reduce vein graft intimal hyperplasia by 20%&#xD;
      compared to aspirin alone at one year following bypass surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vein Graft Intimal Area</measure>
    <time_frame>One year following surgery</time_frame>
    <description>IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vein Graft Angiographic Patency</measure>
    <time_frame>One year following surgery</time_frame>
    <description>Postoperative angiogram 12 months post-CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Coronary Events Within One Year Following Surgery</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Bleeding Events Within One Year Following Surgery</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>75mg Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 mg daily</intervention_name>
    <description>Daily dose of 75 mg Clopidogrel</description>
    <arm_group_label>75mg Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>water pill daily</intervention_name>
    <description>Daily dose of water pill (placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts,&#xD;
             with or without the use of cardiopulmonary bypass.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Valve surgery&#xD;
&#xD;
          -  Redo CABG&#xD;
&#xD;
          -  Left ventricle ejection fraction &lt; 25%&#xD;
&#xD;
          -  Serum creatinine &gt; 130 µmol/L&#xD;
&#xD;
          -  Preoperative use of clopidogrel (with the exception of the current admission)&#xD;
&#xD;
          -  Preoperative use of warfarin; allergy to aspirin or clopidogrel.&#xD;
&#xD;
          -  History of cerebrovascular accident&#xD;
&#xD;
          -  History of severe liver disease&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Current malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ruel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Kulik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Le May, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George A Wells, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry G Mesana, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ottawaheart.ca/</url>
    <description>University of Ottawa Heart Institute Website</description>
  </link>
  <reference>
    <citation>Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996 Sep;28(3):616-26.</citation>
    <PMID>8772748</PMID>
  </reference>
  <reference>
    <citation>Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998 Mar 10;97(9):916-31. Review.</citation>
    <PMID>9521341</PMID>
  </reference>
  <reference>
    <citation>Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992 Feb;89(2):507-11.</citation>
    <PMID>1531345</PMID>
  </reference>
  <reference>
    <citation>Herbert JM, Dol F, Bernat A, Falotico R, Lalé A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998 Sep;80(3):512-8.</citation>
    <PMID>9759636</PMID>
  </reference>
  <reference>
    <citation>Herbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb. 1993 Aug;13(8):1171-9.</citation>
    <PMID>8343491</PMID>
  </reference>
  <reference>
    <citation>Hermann A, Weber AA, Schrör K. Clopidogrel inhibits platelet adhesion and platelet-dependent mitogenesis in vascular smooth muscle cells. Thromb Res. 2002 Jan 15;105(2):173-5.</citation>
    <PMID>11958809</PMID>
  </reference>
  <reference>
    <citation>Harker LA, Marzec UM, Kelly AB, Chronos NR, Sundell IB, Hanson SR, Herbert JM. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation. 1998 Dec 1;98(22):2461-9.</citation>
    <PMID>9832493</PMID>
  </reference>
  <reference>
    <citation>Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000 Jun 20;101(24):2823-8.</citation>
    <PMID>10859288</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001 Jan 23;103(3):363-8.</citation>
    <PMID>11157686</PMID>
  </reference>
  <reference>
    <citation>Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004 Sep 7;110(10):1202-8. Epub 2004 Aug 16.</citation>
    <PMID>15313956</PMID>
  </reference>
  <results_reference>
    <citation>Kulik A, Le May M, Wells GA, Mesana TG, Ruel M. The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med. 2005 Oct 11;6:15.</citation>
    <PMID>16219100</PMID>
  </results_reference>
  <results_reference>
    <citation>Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation. 2010 Dec 21;122(25):2680-7. doi: 10.1161/CIRCULATIONAHA.110.978007. Epub 2010 Dec 6.</citation>
    <PMID>21135365</PMID>
  </results_reference>
  <results_reference>
    <citation>Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011 Oct;92(4):1284-90; discussion 1290-1. doi: 10.1016/j.athoracsur.2011.04.107.</citation>
    <PMID>21958773</PMID>
  </results_reference>
  <results_reference>
    <citation>Une D, Kulik A, Voisine P, Le May M, Ruel M. Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial. Circulation. 2013 Sep 10;128(11 Suppl 1):S213-8. doi: 10.1161/CIRCULATIONAHA.112.000328.</citation>
    <PMID>24030409</PMID>
  </results_reference>
  <results_reference>
    <citation>Une D, Al-Atassi T, Kulik A, Voisine P, Le May M, Ruel M. Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. Circulation. 2014 Sep 9;130(11 Suppl 1):S12-8. doi: 10.1161/CIRCULATIONAHA.113.008227.</citation>
    <PMID>25200049</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <results_first_submitted>March 30, 2021</results_first_submitted>
  <results_first_submitted_qc>March 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2021</results_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Saphenous vein</keyword>
  <keyword>Intimal hyperplasia</keyword>
  <keyword>Coronary artery bypass graft surgery</keyword>
  <keyword>Antiplatelet therapy</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Saphenous vein graft disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>75mg Clopidogrel</title>
          <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
Clopidogrel 75 mg daily: Daily dose of 75 mg Clopidogrel</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
water pill daily: Daily dose of water pill (placebo)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>75mg Clopidogrel</title>
          <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
Clopidogrel 75 mg daily: Daily dose of 75 mg Clopidogrel</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
water pill daily: Daily dose of water pill (placebo)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="7.5"/>
                    <measurement group_id="B2" value="68.1" spread="7.4"/>
                    <measurement group_id="B3" value="66.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vein Graft Intimal Area</title>
        <description>IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed</description>
        <time_frame>One year following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>75mg Clopidogrel</title>
            <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
Clopidogrel 75 mg daily: Daily dose of 75 mg Clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
water pill daily: Daily dose of water pill (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Vein Graft Intimal Area</title>
          <description>IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.0"/>
                    <measurement group_id="O2" value="4.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vein Graft Angiographic Patency</title>
        <description>Postoperative angiogram 12 months post-CABG</description>
        <time_frame>One year following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>75mg Clopidogrel</title>
            <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
Clopidogrel 75 mg daily: Daily dose of 75 mg Clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
water pill daily: Daily dose of water pill (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Vein Graft Angiographic Patency</title>
          <description>Postoperative angiogram 12 months post-CABG</description>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Adverse Coronary Events Within One Year Following Surgery</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>75mg Clopidogrel</title>
            <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
Clopidogrel 75 mg daily: Daily dose of 75 mg Clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
water pill daily: Daily dose of water pill (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Adverse Coronary Events Within One Year Following Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Bleeding Events Within One Year Following Surgery</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>75mg Clopidogrel</title>
            <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
Clopidogrel 75 mg daily: Daily dose of 75 mg Clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
water pill daily: Daily dose of water pill (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Bleeding Events Within One Year Following Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>75mg Clopidogrel</title>
          <description>75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
Clopidogrel 75 mg daily: Daily dose of 75 mg Clopidogrel</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.&#xD;
water pill daily: Daily dose of water pill (placebo)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hospitalization for Coronary Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Minor bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first publication will be a joint effort between all contributing parties. At least 30 days before submission for publication, the partnership will be provided the proposed publication and will be given 30 days to respond with approval or requests for holds. All contributing parties must be acknowledged in all publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marc Ruel</name_or_title>
      <organization>University Of Ottawa Heart Institute</organization>
      <email>mruel@ottawaheart.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

